Distinct metabolic responses of an ovarian cancer stem cell line

BMC Systems Biology

Mark P Styczynski²  John F McDonald¹  Lijuan Wang¹  Kathleen A Vermeersch² 

[1] Ovarian Cancer Institute, School of Biology, and Parker H. Petit Institute of Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Dr, Atlanta 30332-0363, GA, USA;School of Chemical & Biomolecular Engineering and Parker H. Petit Institute for Bioengineering & Bioscience, Georgia Institute of Technology, 311 Ferst Dr, Atlanta 30332-0100, GA, USA

关键词: Biologically-inspired metabolic perturbations;    Cancer metabolism;    Ovarian cancer;    Cancer stem cells;    Metabolomics;   

Others  :  1091259
DOI  :  10.1186/s12918-014-0134-y

 received in 2014-08-28, accepted in 2014-12-10,  发布年份 2014

【 摘 要 】

Background

Cancer metabolism is emerging as an important focus area in cancer research. However, the in vitro cell culture conditions under which much cellular metabolism research is performed differ drastically from in vivo tumor conditions, which are characterized by variations in the levels of oxygen, nutrients like glucose, and other molecules like chemotherapeutics. Moreover, it is important to know how the diverse cell types in a tumor, including cancer stem cells that are believed to be a major cause of cancer recurrence, respond to these variations. Here, in vitro environmental perturbations designed to mimic different aspects of the in vivo environment were used to characterize how an ovarian cancer cell line and its derived, isogenic cancer stem cells metabolically respond to environmental cues.

Results

Mass spectrometry was used to profile metabolite levels in response to in vitro environmental perturbations. Docetaxel, the chemotherapeutic used for this experiment, caused significant metabolic changes in amino acid and carbohydrate metabolism in ovarian cancer cells, but had virtually no metabolic effect on isogenic ovarian cancer stem cells. Glucose deprivation, hypoxia, and the combination thereof altered ovarian cancer cell and cancer stem cell metabolism to varying extents for the two cell types. Hypoxia had a much larger effect on ovarian cancer cell metabolism, while glucose deprivation had a greater effect on ovarian cancer stem cell metabolism. Core metabolites and pathways affected by these perturbations were identified, along with pathways that were unique to cell types or perturbations.

Conclusions

The metabolic responses of an ovarian cancer cell line and its derived isogenic cancer stem cells differ greatly under most conditions, suggesting that these two cell types may behave quite differently in an in vivo tumor microenvironment. While cancer metabolism and cancer stem cells are each promising potential therapeutic targets, such varied behaviors in vivo would need to be considered in the design and early testing of such treatments.

【 授权许可】

   
2014 Vermeersch et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Warburg O: Origin of Cancer Cells. Science 1956, 123:309-314.
• [2]Warburg O, Posener K, Negelein E: On the metabolism of carcinoma cells. Biochem Z 1924, 152:309-344.
• [3]Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
• [4]Kroemer G, Pouyssegur J: Tumor cell metabolism: Cancer’s Achilles’ heel. Cancer Cell 2008, 13:472-482.
• [5]Menendez JA, Oliveras-Ferraros C, Cufi S, Corominas-Faja B, Joven J, Martin-Castillo B, Vazquez-Martin A: Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle 2012, 11:2782-2792.
• [6]Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768.
• [7]Alison MR, Lim SML, Nicholson LJ: Cancer stem cells: problems for therapy? J Pathol 2011, 223:147-161.
• [8]Medema JP: Cancer stem cells: the challenges ahead. Nat Cell Biol 2013, 15:338-344.
• [9]Wang L, Mezencev R, Bowen NJ, Matyunina LV, McDonald JF: Isolation and characterization of stem-like cells from a human ovarian cancer cell line. Mol Cell Biochem 2012, 363:257-268.
• [10]Vermeersch KA, Wang L, Mezencev R, McDonald JF, Styczynski MP: OVCAR-3 spheroid-derived cells display distinct metabolic profiles.PLoS ONE 2014, in press. DOI: 10.1371/journal.pone.0118262.
• [11]Li CP, Chen JS, Chen LT, Yen CJ, Lee KD, Su WP, Lin PC, Lu CH, Tsai HJ, Chao Y: A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Br J Cancer 2010, 103:1343-1348.
• [12]Shimasaki T, Miyazawa K, Moriyama M, Tanaka T, Sato I, Nakaya N, Nakajima H, Kubo A, Suzuki K, Motoo Y: [Combination chemotherapy of docetaxel and UFT against hormone refractory prostate cancer]. Hinyokika Kiyo Acta Urologica Japonica 2011, 57:163-166.
• [13]Tsuchiya A, Imai M, Kamimura H, Togashi T, Watanabe K, Seki K, Ishikawa T, Ohta H, Yoshida T, Kamimura T: Successful treatment of multiple lung metastases of hepatocellular carcinoma by combined chemotherapy with docetaxel, cisplatin and tegafur/uracil. World J Gastroenterol 2009, 15:1779-1781.
• [14]Yang KC, Chao Y, Luo JC, Kuo JY, Lee RC, Li AF, Li CP: The unusual presentation of gastric adenocarcinoma as a testicular mass: a favorable response to docetaxel and Cisplatin plus oral tegafur/uracil and leucovorin. J Chin Med Assoc 2010, 73:88-92.
• [15]Ferreira AK, Freitas VM, Levy D, Ruiz JL, Bydlowski SP, Rici RE, Filho OM, Chierice GO, Maria DA: Anti-angiogenic and anti-metastatic activity of synthetic phosphoethanolamine. PLoS One 2013, 8:e57937.
• [16]Ferreira AK, Meneguelo R, Pereira A, Filho OM, Chierice GO, Maria DA: Synthetic phosphoethanolamine induces cell cycle arrest and apoptosis in human breast cancer MCF-7 cells through the mitochondrial pathway. Biomed Pharmacother 2013, 67:481-487.
• [17]Cabarcas SM, Mathews LA, Farrar WL: The cancer stem cell niche–there goes the neighborhood? Int J Cancer 2011, 129:2315-2327.
• [18]Li Z, Rich JN: Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol 2010, 345:21-30.
• [19]Yvon A-MC, Wadsworth P, Jordan MA: Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999, 10:947-959.
• [20]Lu X, Bennet B, Mu E, Rabinowitz J, Kang Y: Metabolomic changes accompanying transformation and acquisition of metastatic potential in a syngeneic mouse mammary tumor model. J Biol Chem 2010, 285:9317-9321.
• [21]Kind T, Wohlgemuth G, Lee DY, Lu Y, Palazoglu M, Shahbaz S, Fiehn O: FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Anal Chem 2009, 81:10038-10048.
• [22]Wei X, Shi X, Koo I, Kim S, Schmidt RH, Arteel GE, Watson WH, McClain C, Zhang X: MetPP: a computational platform for comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry-based metabolomics. Bioinformatics (Oxford, England) 2013, 29:1786-1792.
• [23]Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, Brown M, Knowles JD, Halsall A, Haselden JN, Nicholls AW, Wilson ID, Kell DB, Goodacre R: Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 2011, 6:1060-1083.
• [24]Xia JG, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS: MetaboAnalyst 2.0-a comprehensive server for metabolomic data analysis. Nucleic Acids Res 2012, 40:W127-W133.